178 related articles for article (PubMed ID: 25149155)
1. CD109 is a potential target for triple-negative breast cancer.
Tao J; Li H; Li Q; Yang Y
Tumour Biol; 2014 Dec; 35(12):12083-90. PubMed ID: 25149155
[TBL] [Abstract][Full Text] [Related]
2. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
3. High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma.
Emori M; Tsukahara T; Murase M; Kano M; Murata K; Takahashi A; Kubo T; Asanuma H; Yasuda K; Kochin V; Kaya M; Nagoya S; Nishio J; Iwasaki H; Sonoda T; Hasegawa T; Torigoe T; Wada T; Yamashita T; Sato N
PLoS One; 2013; 8(12):e84187. PubMed ID: 24376795
[TBL] [Abstract][Full Text] [Related]
4. Decreased expression of autophagy protein LC3 and stemness (CD44+/CD24-/low) indicate poor prognosis in triple-negative breast cancer.
Chang SJ; Ou-Yang F; Tu HP; Lin CH; Huang SH; Kostoro J; Hou MF; Chai CY; Kwan AL
Hum Pathol; 2016 Feb; 48():48-55. PubMed ID: 26772398
[TBL] [Abstract][Full Text] [Related]
5. Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
Dong T; Kang X; Liu Z; Zhao S; Ma W; Xuan Q; Liu H; Wang Z; Zhang Q
Tumour Biol; 2016 Jun; 37(6):8159-68. PubMed ID: 26715276
[TBL] [Abstract][Full Text] [Related]
6. Elevation of CD109 promotes metastasis and drug resistance in lung cancer via activation of EGFR-AKT-mTOR signaling.
Lee KY; Shueng PW; Chou CM; Lin BX; Lin MH; Kuo DY; Tsai IL; Wu SM; Lin CW
Cancer Sci; 2020 May; 111(5):1652-1662. PubMed ID: 32133706
[TBL] [Abstract][Full Text] [Related]
7. CD109 Mediates Cell Survival in Hepatocellular Carcinoma Cells.
Zong G; Xu Z; Zhang S; Shen Y; Qiu H; Zhu G; He S; Tao T; Chen X
Dig Dis Sci; 2016 Aug; 61(8):2303-2314. PubMed ID: 27074923
[TBL] [Abstract][Full Text] [Related]
8. Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression.
Hagikura M; Murakumo Y; Hasegawa M; Jijiwa M; Hagiwara S; Mii S; Hagikura S; Matsukawa Y; Yoshino Y; Hattori R; Wakai K; Nakamura S; Gotoh M; Takahashi M
Pathol Int; 2010 Nov; 60(11):735-43. PubMed ID: 20946523
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of Ezrin and CD44 co‑expression in breast cancer.
Ma L; Jiang T
Oncol Rep; 2013 Oct; 30(4):1899-905. PubMed ID: 23900701
[TBL] [Abstract][Full Text] [Related]
10. Prediction of postoperative survival of triple-negative breast cancer based on nomogram model combined with expression of HIF-1α and c-myc.
Cui J; Jiang H
Medicine (Baltimore); 2019 Oct; 98(40):e17370. PubMed ID: 31577739
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.
Cuppini L; Calleri A; Bruzzone MG; Prodi E; Anghileri E; Pellegatta S; Mancuso P; Porrati P; Di Stefano AL; Ceroni M; Bertolini F; Finocchiaro G; Eoli M
PLoS One; 2013; 8(9):e74345. PubMed ID: 24069296
[TBL] [Abstract][Full Text] [Related]
12. Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy.
Zarotti C; Papassotiropoulos B; Elfgen C; Dedes K; Vorburger D; Pestalozzi B; Trojan A; Varga Z
Sci Rep; 2022 Jan; 12(1):91. PubMed ID: 34997055
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of CD109 expression as a prognostic biomarker in patients with cancer: A systematic review and meta-analysis.
Koh HM; Lee HJ; Kim DC
Medicine (Baltimore); 2021 Mar; 100(11):e25006. PubMed ID: 33725975
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD109 in oral squamous cell carcinoma and its clinical significance.
Chen H; Junji Xu ; Ge R; Liu C
Cell Mol Biol (Noisy-le-grand); 2024 May; 70(5):145-149. PubMed ID: 38814222
[TBL] [Abstract][Full Text] [Related]
15. EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma.
Shen WW; Bièche I; Fuhrmann L; Vacher S; Vincent-Salomon A; Torrino S; Lamaze C
Sci Rep; 2020 May; 10(1):7998. PubMed ID: 32409676
[TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.
Wang RX; Chen S; Huang L; Shao ZM
BMC Cancer; 2018 Sep; 18(1):909. PubMed ID: 30241470
[TBL] [Abstract][Full Text] [Related]
17. High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy.
Na H; Han J; Ka NL; Lee MH; Choi YL; Shin YK; Lee MO
Breast Cancer Res; 2019 Nov; 21(1):127. PubMed ID: 31779659
[TBL] [Abstract][Full Text] [Related]
18. Human kallikrein 5 as a novel prognostic biomarker for triple-negative breast cancer: tissue expression analysis and relationship with disease course.
Yang F; Li JY; Yin QN; Yang K; Dong SN; Bai LJ; Liu P; Tong XW
Genet Mol Res; 2015 Aug; 14(3):9655-66. PubMed ID: 26345898
[TBL] [Abstract][Full Text] [Related]
19. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
[TBL] [Abstract][Full Text] [Related]
20. SWATH™- and iTRAQ-based quantitative proteomic analyses reveal an overexpression and biological relevance of CD109 in advanced NSCLC.
Zhang F; Lin H; Gu A; Li J; Liu L; Yu T; Cui Y; Deng W; Yan M; Li J; Yao M
J Proteomics; 2014 May; 102():125-36. PubMed ID: 24667143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
